⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JANX News
Janux Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
JANX
Form 8-K
sec.gov
JANX
Form 8-K
sec.gov
JANX
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
businesswire.com
JANX
Form 8-K
sec.gov
JANX
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
businesswire.com
JANX
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
businesswire.com
JANX
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
businesswire.com
JANX
BMY
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
businesswire.com
JANX
Form 8-K
sec.gov
JANX